dexmedetomidine has been researched along with sirolimus in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Arora, S; Chaturvedi, A; Heuser, M; Joshi, G; Kumar, R; Patil, S | 1 |
| Chen, C; Chen, X; Han, M; Li, J; Li, Q | 1 |
| Chen, Y; Luo, C; Zhou, Q; Zhu, C | 1 |
1 review(s) available for dexmedetomidine and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for dexmedetomidine and sirolimus
| Article | Year |
|---|---|
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
Topics: Allosteric Regulation; Allosteric Site; Carrier Proteins; Chemistry, Pharmaceutical; Glycolysis; Humans; Membrane Proteins; Protein Kinase Inhibitors; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2022 |
Dexmedetomidine attenuates renal fibrosis via α2-adrenergic receptor-dependent inhibition of cellular senescence after renal ischemia/reperfusion.
Topics: Acute Kidney Injury; Adrenergic alpha-2 Receptor Agonists; Animals; Cellular Senescence; Dexmedetomidine; Fibrosis; Imidazoles; Inflammation; Isoindoles; Kidney; Male; Mice; Mice, Inbred C57BL; Receptors, Adrenergic, alpha-2; Reperfusion Injury; Signal Transduction; Sirolimus | 2018 |
Dexmedetomidine Protects Against Oxygen-Glucose Deprivation-Induced Injury Through Inducing Astrocytes Autophagy via TSC2/mTOR Pathway.
Topics: Adenine; Animals; Astrocytes; Autophagy; Cell Hypoxia; Cells, Cultured; Dexmedetomidine; Drug Evaluation, Preclinical; Glucose; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neuroprotective Agents; Random Allocation; Reperfusion Injury; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein | 2020 |